Glucagon-Like Peptide-1 Receptor Agonists in Patients With Cirrhosis: Answering the Unanswered Questions?

Nonalcoholic fatty liver disease, now termed metabolic dysfunction-associated steatotic liver disease (MASLD),1 continues to be a growing public health issue, with cirrhosis-related mortality increasing at an alarming pace.2 Many studies have researched the use of glucagon-like peptide-1 receptor agonists (GLP1-RA) in patients with MASLD/metabolic dysfunction-associated steatohepatitis with demonstrable effects on reducing liver fat and lowering cardiovascular events.3 In a recent phase 2 trial in patients with metabolic dysfunction-associated steatohepatitis compensated cirrhosis, semaglutide did not significantly improve fibrosis, but it did deliver improvements in weight and glycemic control.
Source: Clinical Gastroenterology and Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research